Chevy Chase Trust Holdings LLC Buys 7,835 Shares of Cencora, Inc. $COR

Chevy Chase Trust Holdings LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 8.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,682 shares of the company’s stock after acquiring an additional 7,835 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.05% of Cencora worth $31,154,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Vestcor Inc lifted its position in Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after purchasing an additional 28 shares during the last quarter. Cornerstone Wealth Group LLC grew its holdings in shares of Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after purchasing an additional 30 shares during the last quarter. Security Financial Services INC. increased its stake in shares of Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after buying an additional 33 shares during the period. Hemington Wealth Management increased its stake in shares of Cencora by 12.0% in the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after buying an additional 35 shares during the period. Finally, Quadcap Wealth Management LLC raised its holdings in Cencora by 1.5% during the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after buying an additional 36 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Down 0.8%

Shares of Cencora stock opened at $349.69 on Monday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12-month low of $252.49 and a 12-month high of $377.54. The company has a market cap of $68.03 billion, a P/E ratio of 42.03, a PEG ratio of 1.63 and a beta of 0.68. The company’s fifty day simple moving average is $355.58 and its two-hundred day simple moving average is $338.81.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company posted $3.73 EPS. Research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Wall Street Analyst Weigh In

COR has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Wells Fargo & Company upped their price objective on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Finally, Bank of America reduced their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $399.00.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,220 shares of company stock worth $5,282,867 over the last three months. Company insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.